TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32838558

Group type: EXPERIMENTAL
Intervention: Educational materials developed based on participant concerns and misconceptions, including a frequently asked questions document and an educational video about broadly neutralizing antibodies.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational materials used during informed consent and throughout trial participation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of behavioral research into clinical trials with broadly neutralizing antibodies.
Number of subjects: 0
Study: 32838740

Group type: EXPERIMENTAL
Intervention: TaperGuard™ ETT
Number of subjects: 15388

Group type: COMPARATOR
Intervention: Standard ETT
Number of subjects: 15388
Study: 32838754

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: copeptin
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 114
Study: 32838772

Group type: EXPERIMENTAL
Intervention: YC-PEM e-PRO
Number of subjects: 139
Study: 32839088

Group type: EXPERIMENTAL
Intervention: ICU admission with severe acute cholangitis (SAC)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Decrease in SOFA score at 48 hours
Number of subjects: 85
Study: 32839276

Group type: EXPERIMENTAL
Intervention: Self-reported smartphone-based sleep measurements
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Automatically generated smartphone-based sleep measurements
Number of subjects: 366

Group type: COMPARATOR
Intervention: Smartphone-based sleep measurements in patients with BD
Number of subjects: 366
Study: 32839491

Group type: EXPERIMENTAL
Intervention: AsiDNA 600 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AsiDNA 900 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AsiDNA (all doses)
Number of subjects: 22
Study: 32840230

Group type: EXPERIMENTAL
Intervention: HUC-MSCs (23×10^6 cells)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Autologous bone-marrow-derived mononuclear cells (BM-MNCs)
Number of subjects: 54
Study: 32840472

Group type: EXPERIMENTAL
Intervention: Radiomic signatures for diagnosing invasive lung adenocarcinoma in PSNs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brock model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical-semantic features
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volumetric models
Number of subjects: 0
Study: 32840580

Group type: EXPERIMENTAL
Intervention: Steamed millet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Stewed lentils
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Complementation of steamed millet with stewed lentils
Number of subjects: 9

Group type: COMPARATOR
Intervention: Reference diet with L-lysine intakes
Number of subjects: 9
Study: 32840736

Group type: EXPERIMENTAL
Intervention: Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy
Number of subjects: 0
Study: 32840872

Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs
Number of subjects: 9145
Study: 32841335

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment before conception (BC)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Levothyroxine treatment after conception (AC)
Number of subjects: 466
Study: 32841541

Group type: EXPERIMENTAL
Intervention: Sorafenib plus doxorubicin (sorafenib 400 mg twice daily and doxorubicin 60 mg/m2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sorafenib plus doxorubicin
Number of subjects: 30
Study: 32841726

Group type: EXPERIMENTAL
Intervention: Right-sided level of neck transection
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Firm pancreatic texture
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: PD for non-pancreatic ductal adenocarcinoma histology
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Full neck resection with systematic transection ≥7 mm at the left side of the portal vein
Number of subjects: 195

Group type: COMPARATOR
Intervention: CR-POPF
Number of subjects: 195

Group type: COMPARATOR
Intervention: Clavien-Dindo ≥ 3 morbidity
Number of subjects: 195

Group type: COMPARATOR
Intervention: Mortality rate
Number of subjects: 195
Study: 32842043

Group type: EXPERIMENTAL
Intervention: HIV-exposed but HIV-negative children
Number of subjects: 4784

Group type: EXPERIMENTAL
Intervention: HIV-positive children
Number of subjects: 4784

Group type: EXPERIMENTAL
Intervention: Children with Apgar scores < 7
Number of subjects: 4784

Group type: EXPERIMENTAL
Intervention: Children not exclusively breast-fed up to 6 months of age
Number of subjects: 4784

Group type: EXPERIMENTAL
Intervention: HIV-exposed and HIV-negative children
Number of subjects: 4784
Study: 32842170

Group type: EXPERIMENTAL
Intervention: Haemophilia carriers during pregnancy and postpartum
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Neonates of haemophilia carriers
Number of subjects: 104

Group type: COMPARATOR
Intervention: Caesarean section
Number of subjects: 104

Group type: COMPARATOR
Intervention: Basal factor level <0.4 IU/mL
Number of subjects: 104
Study: 32842821

Group type: EXPERIMENTAL
Intervention: New surgical approach involving direct bilateral uterine arteries clamping below placental bed after broad ligament opening
Number of subjects: 63

Group type: COMPARATOR
Intervention: Peripartum hysterectomy
Number of subjects: 63
Study: 32842999

Group type: EXPERIMENTAL
Intervention: KORNERSTONE biobank and cohort study
Number of subjects: 0
Study: 32843325

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study: 32843333

Group type: EXPERIMENTAL
Intervention: ClassIntra grade I
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: ClassIntra grade II
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: ClassIntra grade III
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: ClassIntra grade IV
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: ClassIntra
Number of subjects: 2520

Group type: COMPARATOR
Intervention: Postoperative complications assessed with Clavien-Dindo classification
Number of subjects: 2520

Group type: COMPARATOR
Intervention: Intraoperative adverse events assessed with ClassIntra
Number of subjects: 2520
Study: 32843374

Group type: EXPERIMENTAL
Intervention: Living kidney donors
Number of subjects: 306

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 306
Study: 32843490

Group type: EXPERIMENTAL
Intervention: M4112 (100, 200, 400, 600, and 800 mg two times per day orally)
Number of subjects: 15
Study: 32843493

Group type: EXPERIMENTAL
Intervention: CAR-T targeting carcinoembryonic antigen (CEA) delivered via hepatic artery infusion (HAI) using Pressure-Enabled Drug Delivery (PEDD)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Interleukin-2 systemically delivered by continuous intravenous infusion
Number of subjects: 1
Study: 32843804

Group type: EXPERIMENTAL
Intervention: US-guided bilateral ESP block
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: US-guided bilateral OSTAP block
Number of subjects: 70

Group type: COMPARATOR
Intervention: Port site infiltration (control)
Number of subjects: 70
Study: 32843994

Group type: EXPERIMENTAL
Intervention: Community engagement and social support
Number of subjects: 934
Study: 32844207

Group type: EXPERIMENTAL
Intervention: Human milk from obese mothers (OB)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Human milk from normal weight mothers (NW)
Number of subjects: 159
Study: 32844221

Group type: EXPERIMENTAL
Intervention: Higher skeletal muscle mass percentage (SM%) at midlife (1985/1986)
Number of subjects: 1354

Group type: EXPERIMENTAL
Intervention: Body fat percentage (BF%) quartiles in 1985/1986
Number of subjects: 1354

Group type: EXPERIMENTAL
Intervention: Being in the highest SM% quartile at midlife
Number of subjects: 1354

Group type: EXPERIMENTAL
Intervention: Being in the highest BF% quartile at midlife
Number of subjects: 1354
Study: 32844378

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks plus 6-month prednisone taper
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg every 4 weeks plus 6-month prednisone taper
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo every 2 weeks plus 6-month or 12-month prednisone taper
Number of subjects: 161
Study: 32844399

Group type: EXPERIMENTAL
Intervention: Radiotherapy (dosages ranging from 7.5 to 24 Gy)
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with anti-VEGF
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy combined with anti-VEGF
Number of subjects: 2430

Group type: COMPARATOR
Intervention: No radiotherapy treatment
Number of subjects: 2430

Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 2430

Group type: COMPARATOR
Intervention: Very low-dose irradiation (1 Gy)
Number of subjects: 2430
Study: 32844734

Group type: EXPERIMENTAL
Intervention: PLHIV
Number of subjects: 298

Group type: COMPARATOR
Intervention: HIV-
Number of subjects: 298
Study: 32845247

Group type: EXPERIMENTAL
Intervention: Current follow-up situation assessment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Transition readiness evaluation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Comparison of three different transition models
Number of subjects: 58
Study: 32845475

Group type: EXPERIMENTAL
Intervention: Endobronchial coils treatment
Number of subjects: 21
Study: 32845852

Group type: EXPERIMENTAL
Intervention: HEpiTracker app for tracking COVID-19 symptoms, daily body temperature, and health score reporting.
Number of subjects: 477
Study: 32846061

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 55
Study: 32846060

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 105
Study: 32846062

Group type: EXPERIMENTAL
Intervention: Closed-loop system of insulin delivery
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sensor-augmented insulin pump (control group)
Number of subjects: 101
Study: 32847542

Group type: EXPERIMENTAL
Intervention: TPOAb-positive euthyroid women with a female fetus
Number of subjects: 938

Group type: COMPARATOR
Intervention: Euthyroid women (general population)
Number of subjects: 938
Study: 32847548

Group type: EXPERIMENTAL
Intervention: Supreme™ Laryngeal Mask Airway (sLMA) during cesarean delivery with labor
Number of subjects: 584

Group type: COMPARATOR
Intervention: Supreme™ Laryngeal Mask Airway (sLMA) during cesarean delivery without labor
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Supreme™ Laryngeal Mask Airway (sLMA) during cesarean delivery
Number of subjects: 584
Study: 32847746

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200mg) every 3 weeks for three cycles
Number of subjects: 1
Study: 32847826

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes management during hospitalization for COVID-19
Number of subjects: 0
Study: 32847910

Group type: EXPERIMENTAL
Intervention: Culturally informed Family Motivational Engagement Strategy (FAMES)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Implementation toolkit
Number of subjects: 200
Study: 32847933

Group type: EXPERIMENTAL
Intervention: LY3022855 (1.25 mg/kg every 2 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LY3022855 (1.0 mg/kg on weeks 1, 2, 4, and 5)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LY3022855 (100 mg once weekly)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LY3022855 (100 mg every 2 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LY3022855
Number of subjects: 34
Study: 32847948

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 2011

Group type: COMPARATOR
Intervention: CT
Number of subjects: 2011
Study: 32847973

Group type: EXPERIMENTAL
Intervention: Sorafenib, Bevacizumab, and Paclitaxel (Paclitaxel 80 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 32847993

Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Canteen intervention
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no intervention during the first period)
Number of subjects: 162
Study: 32848571

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32848820

Group type: EXPERIMENTAL
Intervention: ReWin(d) group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 33
Study: 32849176

Group type: EXPERIMENTAL
Intervention: Augmented telerehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32849196

Group type: EXPERIMENTAL
Intervention: CT-DRAGON Score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced Features Set
Number of subjects: 0
Study: 32849209

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32849212

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32849235

Group type: EXPERIMENTAL
Intervention: Accelerated Repetitive Transcranial Magnetic Stimulation (TMS)
Number of subjects: 0
Study: 32849281

Group type: EXPERIMENTAL
Intervention: heat-killed yeast-CEA vaccine (NCT01856920)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: avelumab (PD-L1 inhibitor, NCT01772004)
Number of subjects: 1
Study: 32849667

Group type: EXPERIMENTAL
Intervention: Live viral vaccines (including measles-mumps-rubella - MMR)
Number of subjects: 104
Study: 32849914

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) in combination with bevacizumab/oxaliplatin/fluoropyrimidine regimens (mFOLFOX-6/mOXXEL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bevacizumab/oxaliplatin/fluoropyrimidine regimens (mFOLFOX-6/mOXXEL) without VPA
Number of subjects: 0
Study: 32850444

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 0
Study: 32850558

Group type: EXPERIMENTAL
Intervention: Euphrasia Eye Drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32850876

Group type: EXPERIMENTAL
Intervention: Oral Psoralen Plus UV-A (PUVA) Photochemotherapy
Number of subjects: 0
Study: 32850921

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study: 32851257

Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32851490

Group type: EXPERIMENTAL
Intervention: Oral water ingestion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32851578

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) - single radioablation session of 25 Gy
Number of subjects: 15
Study: 32851583

Group type: EXPERIMENTAL
Intervention: Geneva cocktail (caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, fexofenadine)
Number of subjects: 265
Study: 32851663

Group type: COMPARATOR
Intervention: Oral antioxidants (including combinations of antioxidants, N-acetylcysteine, melatonin, L-arginine, myo-inositol, carnitine, selenium, vitamin E, vitamin B complex, vitamin C, vitamin D+calcium, CoQ10, omega-3-polyunsaturated fatty acids)
Number of subjects: 7760

Group type: COMPARATOR
Intervention: Oral antioxidants
Number of subjects: 7760
Study: 32851872

Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study: 32851896

Group type: EXPERIMENTAL
Intervention: Self-alert training (SAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biofeedback training (SAT and PMR)
Number of subjects: 0
Study: 32852696

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 410

Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 410
Study: 32852803

Group type: EXPERIMENTAL
Intervention: Home induction with vaginal prostaglandin E (PGE)
Number of subjects: 1610

Group type: EXPERIMENTAL
Intervention: Home induction with controlled release PGE
Number of subjects: 1610

Group type: EXPERIMENTAL
Intervention: Home induction with balloon or Foley catheter
Number of subjects: 1610
Study: 32853001

Group type: EXPERIMENTAL
Intervention: Behavioral activation training delivered by care managers using a registry checklist.
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Registry-based checklist for training and support.
Number of subjects: 455
Study: 32853224

Group type: EXPERIMENTAL
Intervention: Ultra-processed food (UPF) intake
Number of subjects: 110260
Study: 32853332

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0
Study: 32853411

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 68811

Group type: EXPERIMENTAL
Intervention: Xpert Ultra
Number of subjects: 68811
Study: 32853599

Group type: EXPERIMENTAL
Intervention: Mild illness cohort
Number of subjects: 60

Group type: COMPARATOR
Intervention: Severe pneumonia cohort
Number of subjects: 60
Study: 32853924

Group type: EXPERIMENTAL
Intervention: PAT-MAD (MyTAP™, Airway Management Inc)
Number of subjects: 50
Study: 32854206

Group type: EXPERIMENTAL
Intervention: Self-limiting protocol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control protocol
Number of subjects: 101
Study: 32854536

Group type: EXPERIMENTAL
Intervention: Sequential afatinib followed by osimertinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32854610

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet and moderate-intensity structured exercise intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 37
Study: 32854663

Group type: EXPERIMENTAL
Intervention: Dynamic high-sensitivity troponin levels determined by repeat measurements (rise or fall-pattern)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Troponin levels, clinical symptoms, electrocardiogram, echocardiogram, and coronary angiogram findings
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Coronary angiography early after stroke
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Follow-up at three and twelve months
Number of subjects: 251
Study: 32854671

Group type: EXPERIMENTAL
Intervention: Polar M430 activity tracker (AT) worn for 12 months (6 months intervention + 6 months follow-up)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Polar M430 activity tracker (AT)
Number of subjects: 16
Study: 32854691

Group type: EXPERIMENTAL
Intervention: Qualitative case study involving direct observations, semi-structured interviews, and artifact collection at six NCCN and NCI Comprehensive Cancer Centers.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Interviews with cancer center administrators, providers from various oncology specialties, and patients near end-of-life.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Use of Dedoose software for qualitative data management and analysis.
Number of subjects: 6
Study: 32854836

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR) with contemporary devices (n = 740 with Sapien 3; n = 188 with Evolut R/Pro; n = 106 with others)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR) with calcified raphe and excess leaflet calcification
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR) with both calcified raphe and excess leaflet calcification
Number of subjects: 1034
Study: 32855096

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control
Number of subjects: 220
Study: 32856068

Group type: EXPERIMENTAL
Intervention: Idelalisib 150 mg twice daily
Number of subjects: 6
Study: 32856153

Group type: EXPERIMENTAL
Intervention: FLER analysis and visualization using indocyanine green (0.2 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: FLER values
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lactates at proximal resection site
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ACR
Number of subjects: 22
Study: 32856226

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 104
Study: 32856281

Group type: EXPERIMENTAL
Intervention: Ampreloxetine (2-50 mg, once-daily oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model
Number of subjects: 0
Study: 32856497

Group type: EXPERIMENTAL
Intervention: Lancing devices set at maximum depth (5)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lancing devices set at minimum depth (1)
Number of subjects: 90
Study: 32856597

Group type: EXPERIMENTAL
Intervention: Onduo VDC
Number of subjects: 55
Study: 32856945

Group type: EXPERIMENTAL
Intervention: Prolonged Freezing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Holder Pasteurization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 32857106

Group type: EXPERIMENTAL
Intervention: Cochlear implant
Number of subjects: 34
Study: 32857114

Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bimodal Condition (Cochlear Implant + Hearing Aid)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bimodal Condition
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Unilateral Condition
Number of subjects: 70
Study: 32857176

Group type: EXPERIMENTAL
Intervention: Dietary intake of aromatic amino acids (AAA)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dietary intake of branched-chain amino acids (BCAA)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dietary intake of sulfur amino acids (SAA)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dietary intake of specific amino acids
Number of subjects: 112
Study: 32857268

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 7000

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 7000
Study: 32857293

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 766
Study: 32857327

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol SMI
Number of subjects: 9180